Table 1.
Characteristics of the subjects included in the study
| Case (n=57) | Control (n=57) | p | |
|---|---|---|---|
| Sex (% female) | 28 (49.1) | 36 (63.2) | 0.186 |
| Age | 15.6±3.3 | 15.0±3.9 | 0.493 |
| African ancestry (%) | 83.3±7.6 | 75.6±14.0 | 3.34 × 10−4** |
| FEV1 (% predicted) | 94.8±13.1 | NA | NA |
| FVC (% predicted) | 102.0±14.5 | NA | NA |
| Medication (%) | |||
| Short acting beta agonists | 57 (100) | NA | NA |
| Inhaled corticosteroids1 | 34 (59.7) | NA | NA |
| Long acting beta agonists1 | 12 (21.1) | NA | NA |
| Leukotriene receptor antagonists | 5 (8.8) | NA | NA |
| Positive skin prick test (%)2 | |||
| Any allergen | 27 (58.7) | NA | NA |
| Dust mites | 5 (10.9) | NA | NA |
| Animals | 12 (26.1) | NA | NA |
| Pollens | 20 (43.5) | NA | NA |
| Molds | 8 (17.4) | NA | NA |
| Asthma severity (%) | |||
| Mild Intermittent | 23 (40.4) | NA | NA |
| Mild persistent | 19 (33.3) | NA | NA |
| Moderate persistent | 13 (22.8) | NA | NA |
| Severe persistent | 2 (3.5) | NA | NA |
| Any exacerbation in the past year (%)3 | 18 (34.0) | NA | NA |
1
Subjects taking combo medications are included in these categories.
2
Data available for 46 subjects.
3
Data available for 53 subjects.
For continuous variables, the mean ± the standard deviations are shown.
Abbreviations: FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; NA: Non-Applicable.
**
p < 0.01